miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer
BMC Urology, 05/30/2012Reis ST et al.
The authors' results demonstrate RECK as a target of miR–21. They believe that miR–21 may be important in prostate cancer progression through its regulation of RECK, a known regulator of tumor cell invasion.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.